Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2003 by National Institute on Drug Abuse (NIDA).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
University of California, Los Angeles
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00040040
First received: June 18, 2002
Last updated: February 8, 2007
Last verified: August 2003
  Purpose

The purpose of this study is to assess potential interactions between intravenous (IV) methamphetamine and oral bupropion.


Condition Intervention Phase
Amphetamine-Related Disorders
Drug: Bupropion
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Diagnostic
Official Title: Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between IV Methamphetamine and Oral Bupropion

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Psychological effects
  • BP, HR

Estimated Enrollment: 20
Study Start Date: June 2002
Estimated Study Completion Date: September 2003
Detailed Description:

This is a human laboratory clinical pharmacology study to assess potential interactions between IV methamphetamine challenge and treatment with oral sustained-release bupropion.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Please contact site director for more details.

Exclusion Criteria:

Please contact site director for more details.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00040040

Locations
United States, California
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States, 90024
United States, Texas
University of Texas Health Science Center
Houston, Texas, United States, 77225
Sponsors and Collaborators
University of California, Los Angeles
Investigators
Principal Investigator: Thomas Newton, M.D. National Institute on Drug Abuse (NIDA)
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00040040     History of Changes
Other Study ID Numbers: NIDA-CTO-0010-1
Study First Received: June 18, 2002
Last Updated: February 8, 2007
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Amphetamine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Methamphetamine
Bupropion
Central Nervous System Stimulants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Dopamine Uptake Inhibitors
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs

ClinicalTrials.gov processed this record on August 27, 2014